The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome.
- 2016-12-26
- Journal of applied microbiology 122(1)
- K Nobutani
- D Sawada
- S Fujiwara
- Y Kuwano
- K Nishida
- J Nakayama
- H Kutsumi
- T Azuma
- K Rokutan
- PubMed: 27761980
- DOI: 10.1111/jam.13329
Study Design
- Type
- Clinical Trial
- Population
- patients with irritable bowel syndrome (IBS)
- Methods
- After the patients were administered CP2305 daily for 4 weeks
- Blinding
- Double-blind
- Duration
- 4 weeks
- Funding
- Unclear